Sugi Predict

Sugi Predict / Targets / TSSK2

TSSK2

Testis-specific serine/threonine-protein kinase 2 · Q96PF2 · TSSK2 on Sugi Atlas →

2,228 patent compounds predicted against TSSK2, 1,774 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3078963 SCHEMBL3078963 1.00 2/20
SCHEMBL3082011 SCHEMBL3082011 1.00 2/20
SCHEMBL3077856 SCHEMBL3077856 0.84 2/20
SCHEMBL3075215 SCHEMBL3075215 0.78 2/20
SCHEMBL4852172 SCHEMBL4852172 0.71 2/20
SCHEMBL4858729 SCHEMBL4858729 0.69 2/20
SCHEMBL4850212 SCHEMBL4850212 0.67 2/20
SCHEMBL4849656 SCHEMBL4849656 0.66 2/20
SCHEMBL4854902 SCHEMBL4854902 0.66 2/20
SCHEMBL4855192 SCHEMBL4855192 0.65 2/20
SCHEMBL6233751 SCHEMBL6233751 0.65 2/20
SCHEMBL4853189 SCHEMBL4853189 0.64 2/20
SCHEMBL4858765 SCHEMBL4858765 0.64 2/20
SCHEMBL4848951 SCHEMBL4848951 0.63 2/20
SCHEMBL4857677 SCHEMBL4857677 0.63 2/20
SCHEMBL3072481 SCHEMBL3072481 0.61 2/20
SCHEMBL4855761 SCHEMBL4855761 0.59 2/20
SCHEMBL3061653 SCHEMBL3061653 0.58 2/20
SCHEMBL3084834 SCHEMBL3084834 0.58 2/20
SCHEMBL3080218 SCHEMBL3080218 0.57 2/20

Clinical trials — most relevant to TSSK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Impact of tdrd9 Gene Mutations in the Therapeutic Response to L-carnitine in Oligoasthenozoospermic Men PHASE3ACTIVE_NOT_RECRUITING
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) PHASE3WITHDRAWN
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer PHASE2COMPLETED
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer PHASE1/PHASE2WITHDRAWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease nanRECRUITING
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study nanCOMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
Cause of Familial Testicular Cancer nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Capacitation-associated Protein Tyrosine Phosphorylation As a Possible Biomarker of Sperm Selection nanCOMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Study of Sperm Molecular Factors Implicated in Male Fertility nanCOMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib nanCOMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer nanUNKNOWN
Effect of Environmental Exposures on the Egg Fertilizing Ability of Human Sperm nanCOMPLETED
Azoospermia Patients nanRECRUITING
Reproductive Aging and Obstructive Sleep Apnea nanWITHDRAWN
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
WEST-KOaST Study: WES Analysis of Testicular Cancer Patientsand Their First-degree Family Members nanNOT_YET_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Cryopreservation of Prepubertal Testicular Tissue for Preservation of Fertility in Young Boys With Cancer nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a TSSK2 binder may also engage these)

ProteinNameSimilarity
O54863 — 1.000 O54863 →
TSSK1B Testis-specific serine/threonine-protein kinase 1 0.994 landscape →
Q61241 — 0.991 Q61241 →
Q3SZW1 — 0.987 Q3SZW1 →
Q6SA08 — 0.985 Q6SA08 →
Q852Q2 — 0.983 Q852Q2 →
Q9YHZ5 — 0.980 Q9YHZ5 →
Q6PFQ0 — 0.980 Q6PFQ0 →
Q9JJX8 — 0.979 Q9JJX8 →
Q8BG48 — 0.978 Q8BG48 →
Q28GW8 — 0.977 Q28GW8 →
Q38997 — 0.977 Q38997 →
Q9D411 — 0.977 Q9D411 →
Q91821 — 0.976 Q91821 →
Q9Z265 — 0.976 Q9Z265 →
Q9SN43 — 0.976 Q9SN43 →
Q8C1R0 — 0.976 Q8C1R0 →
MELK Maternal embryonic leucine zipper kinase 0.976 landscape →
P92958 — 0.976 P92958 →
MOK MAPK/MAK/MRK overlapping kinase 0.975 landscape →
STK32A Serine/threonine-protein kinase 32A 0.975 landscape →
Q6U1I9 — 0.975 Q6U1I9 →
Q8BHI9 — 0.975 Q8BHI9 →
Q5HZ38 — 0.975 Q5HZ38 →
Q91XS8 — 0.975 Q91XS8 →
STK32B Serine/threonine-protein kinase 32B 0.975 landscape →
P62205 — 0.974 P62205 →
P52304 — 0.974 P52304 →
Q02111 — 0.974 Q02111 →
Q0JI49 — 0.974 Q0JI49 →